Form SC 13G/A Structure Therapeutics Filed by: WELLINGTON MANAGEMENT GROUP LLP
Structure Therapeutics Inc. (GPCR)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics Inc. (NASDAQ: GPCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
- Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.MarketBeat
- Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of ObesityGlobeNewswire
- Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $80.00 price target on the stock.MarketBeat
GPCR
Sec Filings
- 12/17/24 - Form 8-K
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- GPCR's page on the SEC website